Health TrialsbyHealthPanel

Epidemiological Study on Community Acquired Pneumonia

ConditionCommunity Acquired Pneumonia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCapnetz Stiftung

About this trial

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age ≥ 18

infiltrate on chest X-ray

further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever

Disqualifiers

Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia

Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Trial population

patients with pneumonia

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

20,000 Participants
are grouped into 3 trial groups
Group A: patients with pneumonia
Group B: patients with CAP and HIV
Group C: immunosuppressed patients with CAP

Trial outcomes

Primary outcomes

1

diagnosis

Assessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.

Time frame
2 weeks
2

therapy

Assessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.

Time frame
2 weeks
3

hospitalization

Assessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.

Time frame
2 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Capnetz Stiftung

Lead sponsor

Deutsches Zentrum für Lungenforschung e. V.

Collaborator

Source ClinicalTrials.gov
Apply now